FDA approves Talon’s Marqibo for rare leukemia

WASHINGTON (Reuters) – The Food and Drug Administration said on Thursday it has approved Talon Therapeutics Inc’s Marqibo treatment for adults with a rare form of leukemia known as Philadelphia chromosome negative acute lymphoblastic leukemia. The drug, a targeted version of generic chemotherapy drug vincristine, will be the first commercial product for Talon. The company is majority-owned by Warburg Pincus and Deerfield Management, but shares accounting for a minority portion of its equity trade over-the-counter and were down 5 percent in afternoon trading. …